Home > News > Cell Genesys: The Promise of GVAX
May 7th, 2007
Cell Genesys: The Promise of GVAX
Abstract:
In recent years, there have been some great improvements in the field of cancer therapy thanks to early diagnosis and new forms of therapies, such as monoclonal antibodies and nanoparticle-coated compounds. For over two decades, cancer vaccines have demonstrated impressive results in early pre-clinical trials, which gave rise to great expectations within the scientific community. Unfortunately, scientists couldn't replicate the early phase success into clinical trials, but there are finally some encouraging signs . With several promising candidates which are currently being evaluated in clinical trials, the cancer vaccine field might become the next big thing in cancer therapy.
Source:
biotech.seekingalpha.com
Bookmark:
| Related News Press |
Nanomedicine
New molecular technology targets tumors and simultaneously silences two ‘undruggable’ cancer genes August 8th, 2025
New imaging approach transforms study of bacterial biofilms August 8th, 2025
Cambridge chemists discover simple way to build bigger molecules – one carbon at a time June 6th, 2025
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
Interviews/Book Reviews/Essays/Reports/Podcasts/Journals/White papers/Posters
New molecular technology targets tumors and simultaneously silences two ‘undruggable’ cancer genes August 8th, 2025
Simple algorithm paired with standard imaging tool could predict failure in lithium metal batteries August 8th, 2025
First real-time observation of two-dimensional melting process: Researchers at Mainz University unveil new insights into magnetic vortex structures August 8th, 2025
Lab to industry: InSe wafer-scale breakthrough for future electronics August 8th, 2025
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||